NewLake Capital Partners Inc (QX) (NLCP) News

Form 8-K - Current report

Form 8-K - Current report

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of...

Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Mental Health America’s highest national certification enhances Vistagen’s ongoing efforts to promote mental health throughout the U.S. Vistagen...

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Registration-directed fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder progressing on track PALISADE-3...

U.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices Decline

U.S. index futures are falling in pre-market trading this Monday, amid anticipation for the Federal...

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for...

Form 8-K - Current report

Vistagen to Present at the Jefferies Global Healthcare Conference

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for...

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for...

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference

Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by...

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A pilot study in...